Hibiki Udagawa1, Seiji Niho2, Keisuke Kirita2, Shigeki Umemura2, Shingo Matsumoto2, Kiyotaka Yoh2, Koichi Goto2. 1. Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. hudagawa@east.ncc.go.jp. 2. Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan.
Abstract
PURPOSE: Denosumab reduces the incidence of skeletal-related events (SREs) in solid tumor patients with bone metastases (BM). However, there have been no detailed reports of the efficacy of denosumab in untreated non-squamous non-small cell lung cancer (NSCLC) patients with BM. METHODS: The medical records of patients with untreated non-squamous NSCLC and BM at diagnosis at our institution were reviewed retrospectively. The overall survival (OS) and the time to SREs were analyzed according to the treatment for the BM. RESULTS: Of the total of 149 patients who were eligible, 52 had received denosumab (Dmab group), 51 had received zoledronic acid (ZA group), and 46 had received no treatment (No-Tx group) for the BM. The frequencies of prior SREs were higher in the Dmab group and ZA group than in the No-Tx group (44, 41 and 22%, respectively); however, there were no significant differences in any of the other clinicopathological characteristics examined among the three groups. The median OS in the Dmab group, ZA group and No-Tx group were 21.4 months, 12.7 months and 10.5 months, respectively; the OS was significantly longer in the Dmab group than in the ZA group (P < 0.01). Results of multivariate analysis revealed that denosumab treatment was significantly associated with a more favorable survival [hazard ratio, 0.500; 95% CI 0.332-0.741; P < 0.01]. No significant difference in the time to SREs was observed among the three groups. CONCLUSIONS: Our results suggest that treatment with denosumab may improve the overall survival of non-squamous NSCLC patients with BM.
PURPOSE:Denosumab reduces the incidence of skeletal-related events (SREs) in solid tumorpatients with bone metastases (BM). However, there have been no detailed reports of the efficacy of denosumab in untreated non-squamous non-small cell lung cancer (NSCLC) patients with BM. METHODS: The medical records of patients with untreated non-squamous NSCLC and BM at diagnosis at our institution were reviewed retrospectively. The overall survival (OS) and the time to SREs were analyzed according to the treatment for the BM. RESULTS: Of the total of 149 patients who were eligible, 52 had received denosumab (Dmab group), 51 had received zoledronic acid (ZA group), and 46 had received no treatment (No-Tx group) for the BM. The frequencies of prior SREs were higher in the Dmab group and ZA group than in the No-Tx group (44, 41 and 22%, respectively); however, there were no significant differences in any of the other clinicopathological characteristics examined among the three groups. The median OS in the Dmab group, ZA group and No-Tx group were 21.4 months, 12.7 months and 10.5 months, respectively; the OS was significantly longer in the Dmab group than in the ZA group (P < 0.01). Results of multivariate analysis revealed that denosumab treatment was significantly associated with a more favorable survival [hazard ratio, 0.500; 95% CI 0.332-0.741; P < 0.01]. No significant difference in the time to SREs was observed among the three groups. CONCLUSIONS: Our results suggest that treatment with denosumab may improve the overall survival of non-squamous NSCLCpatients with BM.
Entities:
Keywords:
Bone metastases; Chemotherapy; Denosumab; Non-small cell lung cancer; Survival
Authors: David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand Tombal; Kurt Miller; Paul Sieber; Lawrence Karsh; Ronaldo Damião; Teuvo L Tammela; Blair Egerdie; Hendrik Van Poppel; Joseph Chin; Juan Morote; Francisco Gómez-Veiga; Tomasz Borkowski; Zhishen Ye; Amy Kupic; Roger Dansey; Carsten Goessl Journal: Lancet Date: 2011-11-15 Impact factor: 79.321
Authors: Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ruben Van den Brande; Erwin Mj Cornips; Marc Peeters; Piet Ost; Charlotte Billiet; Erik Van de Kelft Journal: J Bone Oncol Date: 2022-07-09 Impact factor: 4.491
Authors: Angel Qin; Songzhu Zhao; Abdul Miah; Lai Wei; Sandipkumar Patel; Andrew Johns; Madison Grogan; Erin M Bertino; Kai He; Peter G Shields; Gregory P Kalemkerian; Shirish M Gadgeel; Nithya Ramnath; Bryan J Schneider; Khaled A Hassan; Nicholas Szerlip; Zoey Chopra; Sara Journey; Jessica Waninger; Daniel Spakowicz; David P Carbone; Carolyn J Presley; Gregory A Otterson; Michael D Green; Dwight H Owen Journal: J Natl Compr Canc Netw Date: 2021-04-20 Impact factor: 12.693
Authors: Aseala I Abousaud; Meagan S Barbee; Christine C Davis; Sarah E Caulfield; Zeyuan Wang; Alexa Boykin; Bradley C Carthon; Keerthi Gogineni Journal: Ther Adv Med Oncol Date: 2020-12-23 Impact factor: 8.168